 | |
| Clinical data | |
|---|---|
| Other names | Drotebanol, Oxymethebanol |
| AHFS/Drugs.com | International Drug Names |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H27NO4 |
| Molar mass | 333.428 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 165 to 167 °C (329 to 333 °F) |
| |
| |
 N Y (what is this?) (verify) | |
Drotebanol (Oxymethebanol) is amorphinan derivative that acts as anopioid agonist. It was invented bySankyo Company in Japan during the 1970s. It is synthesised fromthebaine.
Drotebanol has powerfulantitussive (cough suppressant) effects, and is around 10x more potent than codeine in producing this effect. It also has analgesic effects several times stronger than codeine, but weaker than morphine.[2] In animal studies it was found to be moderately addictive and produced limited physical dependence, but not as severe as that seen with morphine or pethidine.[3] It was previously marketed for human use under the brand nameMetebanyl, although it is now no longer used in medicine.
It is currently a Schedule I Narcotic controlled substance in the United States with a DEA ACSCN of 9335 and an annual aggregate manufacturing quota of zero.
